Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics
- PMID: 24523596
- PMCID: PMC3921828
- DOI: 10.2147/PGPM.S38295
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics
Abstract
Adenine triphosphate (ATP)-binding cassette (ABC) transporter proteins, such as ABCB1/P-glycoprotein (P-gp) and ABCG2/breast cancer resistance protein (BCRP), transport various structurally unrelated compounds out of cells. ABCG2/BCRP is referred to as a "half-type" ABC transporter, functioning as a homodimer, and transports anticancer agents such as irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), gefitinib, imatinib, methotrexate, and mitoxantrone from cells. The expression of ABCG2/BCRP can confer a multidrug-resistant phenotype on cancer cells and affect drug absorption, distribution, metabolism, and excretion in normal tissues, thus modulating the in vivo efficacy of chemotherapeutic agents. Clarification of the substrate preferences and structural relationships of ABCG2/BCRP is essential for our understanding of the molecular mechanisms underlying its effects in vivo during chemotherapy. Its single-nucleotide polymorphisms are also involved in determining the efficacy of chemotherapeutics, and those that reduce the functional activity of ABCG2/BCRP might be associated with unexpected adverse effects from normal doses of anticancer drugs that are ABCG2/BCRP substrates. Importantly, many recently developed molecular-targeted cancer drugs, such as the tyrosine kinase inhisbitors, imatinib mesylate, gefitinib, and others, can also interact with ABCG2/BCRP. Both functional single-nucleotide polymorphisms and inhibitory agents of ABCG2/BCRP modulate the in vivo pharmacokinetics and pharmacodynamics of these molecular cancer treatments, so the pharmacogenetics of ABCG2/BCRP is an important consideration in the application of molecular-targeted chemotherapies.
Keywords: SNP; kinase inhibitor; molecular target; single-nucleotide polymorphisms.
Figures

Similar articles
-
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. doi: 10.1016/j.addr.2008.07.003. Epub 2008 Dec 3. Adv Drug Deliv Rev. 2009. PMID: 19111841 Review.
-
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11. Cancer Lett. 2018. PMID: 29331420
-
Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.Cancer Lett. 2006 Mar 8;234(1):73-80. doi: 10.1016/j.canlet.2005.04.039. Epub 2005 Nov 21. Cancer Lett. 2006. PMID: 16303243 Review.
-
Role of the breast cancer resistance protein (ABCG2) in drug transport.AAPS J. 2005 May 11;7(1):E118-33. doi: 10.1208/aapsj070112. AAPS J. 2005. PMID: 16146333 Free PMC article.
-
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.Cancer Sci. 2005 Aug;96(8):457-65. doi: 10.1111/j.1349-7006.2005.00081.x. Cancer Sci. 2005. PMID: 16108826 Free PMC article. Review.
Cited by
-
Cancer stem cells and strategies for targeted drug delivery.Drug Deliv Transl Res. 2021 Oct;11(5):1779-1805. doi: 10.1007/s13346-020-00863-9. Epub 2020 Oct 23. Drug Deliv Transl Res. 2021. PMID: 33095384 Free PMC article. Review.
-
Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study.Indian J Pharmacol. 2016 Sep-Oct;48(5):591-594. doi: 10.4103/0253-7613.190761. Indian J Pharmacol. 2016. PMID: 27721549 Free PMC article.
-
The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers.Int J Mol Sci. 2025 May 1;26(9):4310. doi: 10.3390/ijms26094310. Int J Mol Sci. 2025. PMID: 40362545 Free PMC article. Review.
-
MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.PLoS One. 2015 Jun 24;10(6):e0129843. doi: 10.1371/journal.pone.0129843. eCollection 2015. PLoS One. 2015. PMID: 26107945 Free PMC article.
-
A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function.Oncotarget. 2016 Feb 23;7(8):9388-403. doi: 10.18632/oncotarget.7011. Oncotarget. 2016. PMID: 26824187 Free PMC article.
References
-
- Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Re Pharmacol Toxicol. 1999;39:361–398. - PubMed
-
- Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55:3–29. - PubMed
-
- Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998–1009. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous